Report: “[Ivermectin] is expected to be applied as a therapeutic drug (tablet) for all new coronavirus infectious diseases.”
A Japanese conglomerate that is studying the anti-parasitic drug ivermectin has found that the medication had an antiviral effect on Omicron, according to joint non-clinical research.
Kowa Co. Ltd., a conglomerate with interests in trading, hospitality, and electronics, along with health and medical applications, issued a press release (pdf) on Jan. 31 stating that ivermectin has been found to be effective against Omicron in in vitro studies. The firm is also in the process of carrying out a Phase 3 clinical trial on the use of ivermectin to treat COVID-19 patients, though the company’s remarks on effectiveness pertain to the findings of lab-based research.
Kowa representatives didn’t respond to a request for comment by press time.
The company, working with Kitasato University based in Tokyo, said that ivermectin has the “same antiviral effect” on all “mutant strains,” including Alpha, Delta, and Omicron. Kowa added that ivermectin suppresses invasion of the virus and inhibits its replication.
“[Ivermectin] is expected to be applied as a therapeutic drug (tablet) for all new coronavirus infectious diseases,” the report said.
READ THE REST OF THE ARTICLE: The Epoch Times
When I had Covid-19 in November 2020 my functional Medicine Physician prescribed Ivermectin for one week. I recovered…he also prescribed hydroxychloroquine and a host of supplements in high doses.